Trevi Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89532M1018

SecurityTRVI / Trevi Therapeutics, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership16,101 shares
Latest Disclosed Value $ 192,085
Dimensional Fund Advisors Lp reports 55.90% decrease in ownership of TRVI / Trevi Therapeutics, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 16,101 shares of Trevi Therapeutics, Inc. (US:TRVI) valued at $192,085 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 36,510 shares of Trevi Therapeutics, Inc.. This represents a change in shares of -55.90% during the quarter. The current value of the position is $216,558 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F TREVI THERAPEUTICS COM 89532M101 16,101 -20,409 -55.90 192 -57.99 0.0000
2026-02-12 2025-12-31 13F TREVI THERAPEUTICS COM 89532M101 36,510 -4,933 -11.90 457 20.58 0.0001
2025-11-12 2025-09-30 13F TREVI THERAPEUTICS COM 89532M101 41,443 -85,481 -67.35 379 -45.47 0.0001
2025-08-12 2025-06-30 13F TREVI THERAPEUTICS COM 89532M101 126,924 0 0.00 695 -13.02 0.0002
2025-05-13 2025-03-31 13F TREVI THERAPEUTICS COM 89532M101 126,924 -7,429 -5.53 799 44.48 0.0002
2025-02-13 2024-12-31 13F TREVI THERAPEUTICS COM 89532M101 134,353 62,143 86.06 553 129.46 0.0001
2024-11-07 2024-09-30 13F TREVI THERAPEUTICS COM 89532M101 72,210 0 0.00 241 12.62 0.0001
2024-08-09 2024-06-30 13F TREVI THERAPEUTICS COM 89532M101 72,210 49,475 217.62 215 174.36 0.0001
2024-05-10 2024-03-31 13F TREVI THERAPEUTICS COM 89532M101 22,735 22,735 78 0.0000
2024-02-07 2023-12-31 13F TREVI THERAPEUTICS COM 89532M101 0 -18,382 -100.00 0 -100.00
2023-11-09 2023-09-30 13F TREVI THERAPEUTICS COM 89532M101 18,382 18,382 40 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.